IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR Ardelyx Announces Departure of Chief Scientific Officer Read more about Ardelyx Announces Departure of Chief Scientific Officer Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference Read more about Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference Read more about Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C Read more about Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China Read more about Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan Read more about Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline Read more about Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline Roanna Ruiz, Ph.D. - Leerink Partners Roanna Ruiz, Ph.D. Leerink Partners Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress Read more about Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling Read more about Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling Pagination First page « First Previous page ‹ Previous … Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Page 22 Page 23 Page 24 … Next page Next › Last page Last » Subscribe to FAQs Email Alerts Connect
Ardelyx Announces Departure of Chief Scientific Officer Read more about Ardelyx Announces Departure of Chief Scientific Officer
Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference Read more about Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference Read more about Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference
Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C Read more about Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China Read more about Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan Read more about Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline Read more about Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress Read more about Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling Read more about Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling